Twenty-two patients were included (77% female; median age 60 years). Sixty-four percent had sensitizing EGFR mutations, and 32% had an atypical EGFR mutation. Thirteen of the 22 patients (59%) were ...
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
An international research team, with significant involvement from the Medical University of Vienna, has developed a new AI-based analysis method that can accurately classify brain tumors using genetic ...
Recent proteomic studies have offered glimpses into the biology of early Alzheimer’s disease. Two new preprints take this approach further, describing high-throughput surveys that turned up numerous ...
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...
Roche is on a roll: For the second time in less than a year, the company has scored FDA clearance for a pair of assays that can be used together to help spot signs of Alzheimer’s disease. The duo ...
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results